Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Lisata Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 33 | 29 | −4 |
| Shares | 6.67M | 6.27M | −405.7K (−6.1%) |
| Value | $12.9M | $10.1M | −$2.79M (−21.7%) |
New holders (3)
Institutions that held Lisata Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 207,361 | $334.0K | 0.00% |
| Goldman Sachs Group Inc | 53,880 | $87.0K | 0.00% |
| Founders Capital Management | 15,000 | $24.0K | 0.02% |
Sold out (7)
Institutions that held Lisata Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Sabby Management, LLC | 484,970 | $936.0K |
| Dimensional Fund Advisors LP | 61,506 | $119.0K |
| Citadel Advisors LLC | 43,212 | $83.0K |
| Charles Schwab Investment Management Inc | 20,586 | $40.0K |
| Two Sigma Advisers, LP | 13,600 | $26.0K |
| Spire Wealth Management | 12,974 | $25.0K |
| Bank of Montreal | 2,000 | $3.00K |